Abstract
Background Helicobacter suis hosted by hogs is the most-prevalent gastric non-Helicobacter pylori Helicobacter species (NHPH) found in humans with gastric diseases. However, there is no reliable method for diagnosing H. suis infection in clinical practice without gastric biopsy specimens.
Methods Helicobacter infection was diagnosed by using routine methods for detecting H. pylori infection and three other methods (PCR, culture accompanied by genomic analyses, and microscopy) for detecting NHPH and H. pylori infection using gastric biopsy specimens. Then, an ELISA was developed to detect serum anti-H. suis and anti-H. pylori antibody titers.
Findings The serum specimens (n=101) were divided into specimens with (n=20) and without H. suis infection (n=81), or into specimens with (n=17) or without H. pylori infection (n=64) after excluding H. pylori infection-eradicated specimens (n=20). The cut-off values of the optical density in the ELISA were used to judge Helicobacter infections. The sensitivity and specificity were 100% and 92.5%, respectively, for identifying H. suis infection, or 88.2% and 87.5%, respectively, for identifying H. pylori infection, and these levels were considered acceptable for clinical application. We detected no other NHPH infections by PCR or culture in this study.
Interpretation We developed the world’s first ELISA to simultaneously diagnose H. suis and H. pylori infection, which is available for large-scale medical examination. The eradication of H. suis was confirmed by the time-dependent decline of anti-H. suis antibody titers.
Funding This work was supported by MEXT/JSPS KAKENHI (JP19H03474, JP20K08365) and AMED (JP20fk0108148, JP20fk0108133).
Evidence before this study The natural hosts of Helicobacter suis, a member of the gastric non-Helicobacter pylori Helicobacter species (NHPH), are monkeys and hogs, while other NHPH such as H. heilmannii sensu stricto (s.s.), H. ailurogastricus, H. felis, H. salomonis, H. baculiformis, H. cynogastricus, and H. bizzozeronii infect the stomachs of cats and dogs. Among humans with NHPH infections, H. suis infection is most common. However, H. suis from gastric biopsy specimens could not be grown as a pure culture until our recent success growing H. suis from the gastric biopsies of patients suffering from gastric diseases. Recent studies suggest that H. suis infection leads to gastric diseases such as MALT lymphoma, nodular gastritis, chronic gastritis, and peptic ulcer. Because routine diagnostic methods based on the urease activity of NHPH, such as the urea breath test (UBT) and rapid urease test (RUT), often yield negative results in the case of H. suis infecting the human stomach, PCR or histological examination from gastric biopsy specimens has been performed to diagnose H. suis infection for research purposes. Therefore, in patients with gastric diseases caused by H. suis infection, physicians often miss the window for eradication treatment.
The added value of this study This study is the first to develop a serological diagnostic method for H. suis infection in humans. The diagnostic procedure identified all the H. suis infections that had been identified in advance by PCR and culture of gastric biopsy specimens. The ELISA showed low cross-reactivity between H. suis and H. pylori infection. Because NHPH other than H. suis were not detected in the human stomach in this study, the development of a comprehensive approach for identifying H. suis and H. pylori infection could lead to an accurate diagnosis of gastric Helicobacter infection.
Implications of all the available evidence Most Helicobacter pylori infections occurs in infects infancy in developed countries, usually via transmission from their family members. Meanwhile, the infection period and route of H. suis from hogs remain unclear. Because the post-H. pylori eradication era has already begun in Japan, a possible surge in the H. suis infection rate may already have induced many cases of gastric disease in the Japanese population. Therefore, a method for comprehensive clinical diagnosis and effective eradication would be helpful as a plan of action for Helicobacter infections.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by MEXT/JSPS KAKENHI (JP19H03474, JP20K08365) and AMED (JP20fk0108148, JP20fk0108133).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Research Ethics Committees (REC) of the National Institute of Infectious Diseases (NIID) and Kitasato University approved this study under registration numbers 1284 and 18100, respectively. The ethical review was also approved at the following eight medical institutions: Junpukai Health Maintenance Center, Kyorin University Hospital, Tokai University Hospital, Toyama University Hospital, Takeda Hospital, Aichi Medical University Hospital, Kakogawa Central Municipal Hospital, and Kanazawa Municipal Hospital.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos